Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HROW NASDAQ:PTCT NASDAQ:PTGX NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHROWHarrow$39.44+0.2%$40.65$20.85▼$59.23$1.46B0.27957,874 shs586,742 shsPTCTPTC Therapeutics$68.51+3.7%$56.65$35.51▼$69.26$5.25B0.551.23 million shs1.41 million shsPTGXProtagonist Therapeutics$77.68+1.0%$61.52$33.31▼$93.25$4.79B2.21.65 million shs1.15 million shsTGTXTG Therapeutics$35.05+2.7%$31.89$22.61▼$46.48$5.42B1.971.81 million shs1.50 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHROWHarrow+0.20%-0.75%-7.89%+9.13%-26.27%PTCTPTC Therapeutics+3.66%+6.25%+16.16%+41.17%+82.40%PTGXProtagonist Therapeutics+0.96%+18.96%+33.06%+37.63%+63.06%TGTXTG Therapeutics+2.67%-1.96%+10.39%-10.56%+42.65%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHROWHarrow$39.44+0.2%$40.65$20.85▼$59.23$1.46B0.27957,874 shs586,742 shsPTCTPTC Therapeutics$68.51+3.7%$56.65$35.51▼$69.26$5.25B0.551.23 million shs1.41 million shsPTGXProtagonist Therapeutics$77.68+1.0%$61.52$33.31▼$93.25$4.79B2.21.65 million shs1.15 million shsTGTXTG Therapeutics$35.05+2.7%$31.89$22.61▼$46.48$5.42B1.971.81 million shs1.50 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHROWHarrow+0.20%-0.75%-7.89%+9.13%-26.27%PTCTPTC Therapeutics+3.66%+6.25%+16.16%+41.17%+82.40%PTGXProtagonist Therapeutics+0.96%+18.96%+33.06%+37.63%+63.06%TGTXTG Therapeutics+2.67%-1.96%+10.39%-10.56%+42.65%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHROWHarrow 2.67Moderate Buy$68.5073.68% UpsidePTCTPTC Therapeutics 2.53Moderate Buy$69.000.72% UpsidePTGXProtagonist Therapeutics 2.83Moderate Buy$72.00-7.31% DownsideTGTXTG Therapeutics 2.67Moderate Buy$49.0039.80% UpsideCurrent Analyst Ratings BreakdownLatest HROW, PTGX, TGTX, and PTCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/13/2025PTGXProtagonist TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform10/13/2025PTGXProtagonist TherapeuticsJohnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$112.0010/8/2025HROWHarrowWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025PTCTPTC TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/8/2025PTGXProtagonist TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/8/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.0010/8/2025TGTXTG TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/7/2025PTGXProtagonist TherapeuticsJohnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$74.0010/6/2025TGTXTG TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.0010/6/2025TGTXTG TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.0010/1/2025HROWHarrowB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$70.00 ➝ $74.00(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHROWHarrow$199.61M7.31$0.14 per share287.84$1.95 per share20.23PTCTPTC Therapeutics$1.76B3.08N/AN/A($14.24) per share-4.81PTGXProtagonist Therapeutics$209.18M23.10$4.56 per share17.03$11.33 per share6.86TGTXTG Therapeutics$454.07M12.25$0.12 per share284.59$1.43 per share24.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHROWHarrow-$17.48M-$0.25N/A98.60N/A-4.49%-2.18%-0.35%11/12/2025 (Estimated)PTCTPTC Therapeutics-$363.30M$6.979.83N/AN/A35.65%-106.31%30.61%11/6/2025 (Estimated)PTGXProtagonist Therapeutics$275.19M$0.70110.97N/AN/A24.88%8.12%7.41%11/6/2025 (Estimated)TGTXTG Therapeutics$23.38M$0.3794.7335.05N/A13.31%26.05%9.58%11/3/2025 (Estimated)Latest HROW, PTGX, TGTX, and PTCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025HROWHarrow$0.11N/AN/AN/A$73.70 millionN/A11/6/2025Q3 2025PTCTPTC Therapeutics-$1.11N/AN/AN/A$177.42 millionN/A11/6/2025Q3 2025PTGXProtagonist Therapeutics-$0.59N/AN/AN/A$5.41 millionN/A11/3/2025Q3 2025TGTXTG Therapeutics$0.24N/AN/AN/A$152.12 millionN/A8/11/2025Q2 2025HROWHarrow$0.01$0.24+$0.23$0.13$64.23 million$63.74 million8/7/2025Q2 2025PTCTPTC Therapeutics-$1.07-$0.83+$0.24-$0.83$173.01 million$178.88 million8/6/2025Q2 2025PTGXProtagonist Therapeutics-$0.53-$0.55-$0.02-$0.55$8.32 million$5.55 million8/4/2025Q2 2025TGTXTG Therapeutics$0.32$0.17-$0.15$0.17$147.76 million$141.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHROWHarrowN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHROWHarrow0.780.620.58PTCTPTC TherapeuticsN/A3.623.57PTGXProtagonist TherapeuticsN/A16.9716.97TGTXTG Therapeutics0.893.862.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHROWHarrow72.76%PTCTPTC TherapeuticsN/APTGXProtagonist Therapeutics98.63%TGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipHROWHarrow15.16%PTCTPTC Therapeutics5.50%PTGXProtagonist Therapeutics4.90%TGTXTG Therapeutics10.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHROWHarrow18037.00 million31.39 millionOptionablePTCTPTC Therapeutics1,41079.44 million75.07 millionOptionablePTGXProtagonist Therapeutics12062.21 million59.16 millionOptionableTGTXTG Therapeutics290158.67 million141.78 millionOptionableHROW, PTGX, TGTX, and PTCT HeadlinesRecent News About These CompaniesTG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of "Moderate Buy" from AnalystsOctober 12, 2025 | marketbeat.comBrokers Offer Predictions for TG Therapeutics Q3 EarningsOctober 10, 2025 | americanbankingnews.comTG Therapeutics (NASDAQ:TGTX) Given Hold (C-) Rating at Weiss RatingsOctober 9, 2025 | marketbeat.comAnalysts Offer Predictions for TG Therapeutics Q3 EarningsOctober 8, 2025 | marketbeat.comHC Wainwright Weighs in on TG Therapeutics FY2029 EarningsOctober 7, 2025 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Raised to "Strong-Buy" at HC WainwrightOctober 7, 2025 | marketbeat.comTG Therapeutics assumed with a Buy at H.C. WainwrightOctober 6, 2025 | msn.comWhat TG Therapeutics (TGTX)'s Six-Year BRIUMVI Safety Data Means For ShareholdersOctober 4, 2025 | uk.finance.yahoo.comInstitutional investors are TG Therapeutics, Inc.'s (NASDAQ:TGTX) biggest bettors and were rewarded after last week's US$176m market cap gainOctober 4, 2025 | finance.yahoo.comTG announces updated data presentations from ULTIMATE I, II Phase 3 trialsSeptember 25, 2025 | msn.comTG Therapeutics, Inc.: New Data for BRIUMVI Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous ...September 24, 2025 | finanznachrichten.deTG Therapeutics Reports Six-Year Data for BRIUMVI® Showing Exceptional Efficacy and Consistent Safety Profile in Multiple Sclerosis TreatmentSeptember 24, 2025 | quiverquant.comQNew Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI TreatmentSeptember 24, 2025 | globenewswire.comWhat is B. Riley's Forecast for TG Therapeutics Q4 Earnings?September 20, 2025 | marketbeat.comStrs Ohio Makes New Investment in TG Therapeutics, Inc. $TGTXSeptember 20, 2025 | marketbeat.comWhat is B. Riley's Estimate for TG Therapeutics Q3 Earnings?September 19, 2025 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 18, 2025 | marketbeat.comB. Riley Forecasts Strong Price Appreciation for TG Therapeutics (NASDAQ:TGTX) StockSeptember 18, 2025 | marketbeat.comTG Therapeutics price target raised to $55 from $53 at B. RileySeptember 17, 2025 | msn.comTG Therapeutics, Inc. $TGTX Position Increased by Voya Investment Management LLCSeptember 17, 2025 | marketbeat.comInsider Selling: TG Therapeutics (NASDAQ:TGTX) Director Sells 20,852 Shares of StockSeptember 13, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHROW, PTGX, TGTX, and PTCT Company DescriptionsHarrow NASDAQ:HROW$39.44 +0.08 (+0.20%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$39.40 -0.04 (-0.10%) As of 06:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.PTC Therapeutics NASDAQ:PTCT$68.51 +2.42 (+3.66%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$69.73 +1.22 (+1.78%) As of 05:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Protagonist Therapeutics NASDAQ:PTGX$77.68 +0.74 (+0.96%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$77.89 +0.20 (+0.26%) As of 06:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.TG Therapeutics NASDAQ:TGTX$35.05 +0.91 (+2.67%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$34.80 -0.25 (-0.72%) As of 10/15/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability 3 Healthcare Companies Insiders Are Buying Tempus AI Hits $100—Are Shares Due for a Pullback? Vertiv Stock Surges on Strategic CFO Hire and AI Momentum NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
